We are closer than ever, but still years away from walking into a dentist’s office and growing a new tooth. The most advanced effort, led by a Japanese research team, began first-in-human clinical trials in 2024 and is targeting general availability around 2030. That timeline is optimistic and applies initially to a narrow group of patients born without a full set of teeth, not to the millions of people who’ve lost teeth to decay, injury, or gum disease. Still, the science behind it represents a genuine breakthrough, not just hype.
The Drug That Could Regrow Teeth
The leading approach doesn’t involve stem cell implants or 3D-printed scaffolds. It’s a drug, specifically an antibody that blocks a single protein your body already makes. That protein, called USAG-1, acts like a brake on tooth growth. It suppresses two key signaling pathways that control how dental stem cells develop into enamel, dentin, and pulp. During normal development, USAG-1 keeps everything balanced so you don’t grow extra teeth. But once your adult teeth are in, that same protein effectively locks the door on any further tooth formation.
The idea is simple: remove the brake. When researchers knocked out or blocked USAG-1 in animal models, the animals grew extra teeth. More importantly, those teeth took on the correct shape for their location in the jaw. Teeth that grew in the incisor region looked like incisors; teeth in the molar region looked like molars. This wasn’t random bone growth. The body seemed to know what kind of tooth belonged where.
What the Animal Studies Showed
The drug has been tested in both mice and ferrets, each chosen for different reasons. Mice with genetic mutations that cause missing teeth were given a single dose of the antibody. In those animals, the treatment corrected the tooth deficiency and promoted normal tooth formation in a dose-dependent way, meaning higher doses produced more consistent results. In mice that lacked USAG-1 entirely, researchers observed extra teeth and even reactivation of what appears to be a dormant “third dentition,” a set of tooth buds beyond baby teeth and adult teeth that most mammals never develop.
Ferrets were a more meaningful test because their teeth are closer to human teeth in size and structure. Systemic injection of the antibody in ferrets successfully regenerated a tooth resembling this third dentition. The results were encouraging enough to move the work toward human testing, though the researchers noted that the antibody did not prevent tooth loss in cases where teeth were already failing, only stimulated new growth.
Where Human Trials Stand
A team based at Kitano Hospital in Osaka began the first-in-human clinical trial in mid-2024. Before reaching that point, they completed preclinical safety and dosing studies starting in April 2022 and went through formal regulatory consultations with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) to determine what safety, pharmacokinetic, and pharmacological testing was required. The protocol has been finalized and the trial is underway.
The first patients enrolled are adults with congenital tooth agenesis, a condition where some or all permanent teeth never developed. This is the most common developmental dental abnormality in humans and can be caused by mutations in several genes. Some people are missing just a few teeth; others are missing most of them. By starting with this population, researchers can test whether the drug triggers new tooth growth in people whose bodies have the biological machinery for teeth but never fully activated it.
The team’s stated goal is to have the drug ready for general use by 2030. That would be remarkably fast for a first-in-class medication, and the timeline will depend heavily on how the early trials go, whether the drug proves safe at effective doses, and how quickly it can move through later-phase trials with larger patient groups.
The Enamel Problem
Even with promising results, one significant challenge remains: enamel. Growing dentin (the hard tissue beneath the surface) and dental pulp (the living core with nerves and blood supply) appears achievable through this pathway. But enamel, the ultra-hard outer coating that makes teeth functional for biting and chewing, is notoriously difficult to regenerate. It forms only when epithelial and mesenchymal cells interact in a very precise sequence during development. A systematic review of whole-tooth regeneration in animal models found that enamel regeneration succeeds only when those interactions are replicated exactly, something that’s hard to control with a systemic drug.
This doesn’t necessarily mean regenerated teeth would be useless. But it does raise questions about whether a regrown tooth would be durable enough to function like a natural one without additional dental work, such as a crown to protect its surface.
What About Stem Cell Approaches?
The antibody drug isn’t the only tooth regeneration strategy in development. Stem cell-based methods have been explored for years, particularly for regenerating dental pulp in teeth that have undergone root canal treatment. In a small human study, dental pulp stem cells were transplanted into five patients with severe pulp inflammation. After 24 weeks, three of the five showed complete pulp regeneration with new dentin formation, and four of five had restored nerve activity in the treated tooth.
A newer variation skips the cell transplant entirely. Instead of harvesting stem cells and reimplanting them, researchers use signaling molecules to recruit the patient’s own stem cells into the damaged area. This “cell homing” approach is less invasive and avoids some of the complexity of handling live cells in a lab. It’s still in early stages, but the concept has been validated in proof-of-concept research.
These stem cell methods differ from the antibody approach in an important way. They’re focused on repairing or regenerating tissue inside an existing tooth, not growing an entirely new one from scratch. For someone with a damaged tooth that still has its root structure, stem cell pulp regeneration could eventually be an alternative to a root canal. For someone missing a tooth entirely, the antibody drug is the more relevant technology.
Who Will Get Access First
If the drug reaches the market by 2030, it will almost certainly be approved first for people with congenital tooth agenesis. This is a population with a clear medical need and a condition directly linked to the biological pathways the drug targets. Expanding to people who’ve lost teeth through decay, trauma, or aging would require additional trials to prove the drug works in a very different biological context, one where the jaw may have remodeled, bone density may have changed, and the dormant tooth buds the drug relies on may or may not still be present.
There are no reliable cost estimates yet for the treatment. The only available economic data in regenerative dentistry compares existing techniques like regenerative endodontics to conventional root canal alternatives, and those numbers don’t translate to a completely new class of drug. Pricing will depend on manufacturing complexity, dosing requirements, and whether the treatment involves a single injection or a longer course. Given that dental implants currently cost several thousand dollars per tooth, a drug-based alternative could be competitive even at a high price point, but that’s speculation at this stage.
A Realistic Timeline
For people born without teeth, a working treatment could realistically arrive in the late 2020s or early 2030s, assuming clinical trials go well. For the average person who lost a tooth to a cavity or a fall, the timeline is longer and less certain. The biology is promising, the animal data is strong, and the first human trial is already running. But drug development is full of surprises, and the leap from “it works in mice and ferrets” to “it safely and reliably grows functional teeth in adults” is a large one.
What makes this moment different from past tooth regeneration headlines is that a specific drug has cleared regulatory review, entered human trials, and has a defined path to market. That’s not a lab curiosity. It’s a product in development, with all the uncertainty but also all the infrastructure that entails.